Brokerages Set Cellebrite DI Ltd. (NASDAQ:CLBT) PT at $18.57

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Get Free Report) have received a consensus recommendation of "Buy" from the eight ratings firms that are currently covering the firm, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a buy recommendation. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $18.57.

CLBT has been the topic of several recent analyst reports. Bank of America boosted their target price on shares of Cellebrite DI from $13.00 to $17.00 and gave the company a "buy" rating in a report on Friday, August 16th. JPMorgan Chase & Co. boosted their target price on shares of Cellebrite DI from $14.00 to $15.00 and gave the company an "overweight" rating in a report on Wednesday, August 14th. Needham & Company LLC boosted their target price on shares of Cellebrite DI from $14.00 to $17.00 and gave the company a "buy" rating in a report on Friday, August 16th. TD Cowen boosted their target price on shares of Cellebrite DI from $20.00 to $23.00 and gave the company a "buy" rating in a report on Monday, September 23rd. Finally, Craig Hallum boosted their target price on shares of Cellebrite DI from $20.00 to $23.00 and gave the company a "buy" rating in a report on Wednesday, September 25th.

Cellebrite DI Stock Up 0.2 %

NASDAQ CLBT traded up $0.03 during trading hours on Thursday, hitting $17.94. 484,609 shares of the company's stock traded hands, compared to its average volume of 1,124,494. Cellebrite DI has a 52-week low of $6.36 and a 52-week high of $18.75. The firm's 50-day moving average is $17.18 and its 200-day moving average is $13.65.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its quarterly earnings data on Thursday, August 15th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.02. The company had revenue of $95.70 million during the quarter, compared to analysts' expectations of $91.94 million. Cellebrite DI had a negative net margin of 28.51% and a positive return on equity of 5,902.06%. Cellebrite DI's revenue was up 24.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.05 EPS. As a group, sell-side analysts predict that Cellebrite DI will post 0.31 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Point72 Asia Singapore Pte. Ltd. grew its position in shares of Cellebrite DI by 59.6% in the 2nd quarter. Point72 Asia Singapore Pte. Ltd. now owns 2,724 shares of the company's stock valued at $33,000 after buying an additional 1,017 shares during the last quarter. Pathway Financial Advisers LLC boosted its stake in Cellebrite DI by 1,583.8% during the 3rd quarter. Pathway Financial Advisers LLC now owns 4,378 shares of the company's stock worth $74,000 after purchasing an additional 4,118 shares during the period. Public Employees Retirement Association of Colorado acquired a new stake in Cellebrite DI during the 2nd quarter worth $71,000. nVerses Capital LLC acquired a new stake in Cellebrite DI during the 2nd quarter worth $103,000. Finally, TD Asset Management Inc acquired a new stake in Cellebrite DI during the 2nd quarter worth $121,000. 45.88% of the stock is owned by hedge funds and other institutional investors.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.